Semaglutide Smoking Cessation Trial Opens Recruiting in Diabetes

What is the semaglutide smoking cessation trial testing?

The study, listed on ClinicalTrials.gov under the identifier NCT07059377 with a record dated September 8, 2026, is recruiting participants who have diabetes and smoke. Its sponsor is the Ottawa Heart Institute Research Corporation. The registry lists it as a Phase 3 study with a planned enrollment of 100 people, and describes its aim as assessing the feasibility of running a randomized controlled trial on this question.

The intervention under study is semaglutide, a glucagon-like peptide-1 receptor agonist sold under the brand names Ozempic, Wegovy and Rybelsus, used as an adjunct to combination nicotine replacement therapy. Combination NRT refers to pairing a long-acting nicotine source, such as a patch, with a short-acting one, such as gum or lozenges, and is already standard smoking-cessation care in many settings.

The registry framing matters. According to the trial record, the objective is to determine whether an effectiveness trial can be conducted, which typically means the investigators are measuring things like recruitment rate, retention and protocol adherence alongside any preliminary signal on abstinence. No results have been posted, and none should be expected from a study that has only just opened to enrollment.

Why are GLP-1 drugs being studied for addiction at all?

Interest in incretin drugs and substance use grew out of observational reports and preclinical work suggesting that GLP-1 receptor signaling influences reward pathways in the brain, not only appetite and gastric emptying. Because GLP-1 receptors are expressed in brain regions involved in motivation, researchers have asked whether drugs that act on those receptors might blunt cravings for things other than food, including nicotine and alcohol.

Doing that trial in people with diabetes has a practical logic. Semaglutide is already prescribed for type 2 diabetes, smoking substantially worsens cardiovascular risk in that population, and weight gain after quitting is a well-known deterrent to stopping. A cessation study built on top of an existing indication sidesteps some of the questions that would arise from giving a metabolic drug to otherwise healthy smokers.

None of that is evidence that semaglutide helps anyone quit smoking. The mechanism is plausible and the hypothesis is testable, which is precisely why a feasibility trial exists. Readers should treat the registration as a signal that the question is being asked seriously, not as a finding.

If you are tracking an existing prescription while this research develops, the semaglutide dosage calculator can help you keep your own records consistent between appointments.

According to the trial's ClinicalTrials.gov registration, the study is recruiting 100 participants with diabetes to assess the feasibility of a randomized controlled trial of semaglutide as an adjunct to combination nicotine replacement therapy.

How a feasibility trial differs from a pivotal trial

A feasibility or pilot randomized controlled trial is designed to answer whether a larger study can be run, and how. With 100 participants, a study is generally not powered to detect modest differences in a binary outcome such as sustained abstinence at six or twelve months. What it can establish is whether enough eligible smokers with diabetes will enroll, whether they stay in the study, and whether the combined intervention is tolerated well enough to continue.

Phase labels can be confusing here. The registry lists this as Phase 3, a designation that ordinarily implies a large confirmatory efficacy study, but the description explicitly frames the work as feasibility assessment. Registry phase fields are entered by sponsors and do not always map neatly onto the size or ambition of the protocol, which is one reason reading the study description matters more than reading the label.

If the feasibility endpoints are met, the usual next step is a multi-site trial with enrollment in the thousands and abstinence confirmed biochemically. That is a multi-year path. Anyone treating this registration as evidence that a new use is near would be reading years ahead of the data.

Recording cravings and behavioral changes alongside physical symptoms is a straightforward extension of side-effect logging.

The registry entry for NCT06864026 lists Eli Lilly as sponsor of a Phase 4 study enrolling 200 participants with active psoriatic arthritis and overweight or obesity for up to 12 months. the registry entry for NCT06864026.

Other GLP-1 and tirzepatide studies registered this week

The smoking cessation study is not the only incretin trial to surface in registries and journals this week. Eli Lilly has a Phase 4 study, NCT06864026, listed as recruiting 200 participants to assess adding tirzepatide to ixekizumab therapy in people with active psoriatic arthritis who also have overweight or obesity with at least one weight-related comorbidity. The record describes a study lasting up to 12 months conducted in standard clinical practice.

Separately, researchers publishing in EClinicalMedicine reported a retrospective multicenter cohort study in the United States comparing GLP-1 receptor agonists with mineralocorticoid receptor antagonists as fourth-line drug therapy in patients with resistant hypertension and overweight or obesity. Retrospective cohort work of this kind can describe associations in real-world records but cannot establish that one drug class causes better blood pressure outcomes than another.

A third item, published in Immunopharmacology and Immunotoxicology, is a report from Blitshteyn and colleagues describing improvement of post-COVID-19 vaccination dysautonomia with a GLP-1 receptor agonist. Reports of that type describe individual clinical courses and are hypothesis-generating only. Taken together, the week's output shows the incretin literature spreading across rheumatology, cardiology, autonomic medicine and addiction, most of it still at the earliest stages of evidence.

Feasibility studies live or die on retention, which is the clinical-trial version of the adherence tracking any long-running protocol depends on.

The published cohort study in EClinicalMedicine compared GLP-1 receptor agonists with mineralocorticoid receptor antagonists as fourth-line pharmacological therapy in patients with resistant hypertension and overweight or obesity. the published cohort study in EClinicalMedicine.

What remains unresolved

The central unknown is simple: nobody yet knows whether semaglutide changes smoking behavior in a controlled setting. Observational signals have circulated for a couple of years, but observational data on people already taking a drug for another reason cannot separate the drug's effect from the characteristics of the people who receive it. That is what randomization exists to fix, and this study is the preliminary step toward it.

There are also open questions about who any such finding would apply to. A trial restricted to people with diabetes, with a target of 100 participants, will not tell you much about smokers without metabolic disease. And because the comparator involves nicotine replacement in both arms, any eventual result would speak to semaglutide as an add-on rather than as a standalone cessation aid.

Finally, the registry record is a plan, not a completed study. Enrollment targets are missed, protocols are amended and trials are withdrawn. The record's status is worth rechecking rather than assuming the study proceeds as described.

Readers following the psoriatic arthritis study may also use the tirzepatide dosage calculator to keep their own log aligned with what their prescriber set.